Therapeutic methods in the treatment of triple-negative breast cancer - a review
DOI:
https://doi.org/10.12775/JEHS.2022.12.07.078Keywords
breast cancer, triple-negative, surgery, chemotherapy, immunotherapy, targeted therapyAbstract
Breast cancer is a common female malignancy characterized by the presence of multiple subtypes taking into account, among other things, hormonal activity. The purpose of this study is to show the therapeutic options for triple-negative breast cancer (TNBC). A review of the literature in databases such as PubMed, Google Scholar, and Web of Science by keywords was performed, taking into account papers from 2017-2022. The main therapeutic approaches are surgical intervention and systemic chemotherapy (neoadjuvant and adjuvant). Unsatisfactory results from chemotherapy have prompted researchers to work on other methods to combat TNBC. Clinical trials are being conducted on the use of immunotherapy focusing mainly on molecules against PD-1, PD-L1, and CTLA-4. Targeted therapy is the latest proposed form of therapy, which offers the possibility of introducing a drug in the future that will be tailored to the patient's needs limiting the negative therapeutic impact.
References
Hedrick Elleson L., C. Lester Susan: Żeński układ płciowy i pierś [Female reproductive system and breast], [w:] Robbins. Patologia. Wydanie X., Kumar V., Abbas A. K., Aster J., (red.). T. Olszewski W. (red. pol.) Wyd. Edra Urban & Partner, Wrocław, 2019, 835-872.
Winters S., Martin C.., Murphy D, Shokar NK., Breast Cancer Epidemiology, Prevention, and Screening., Prog Mol Biol Transl Sci. 2017;151:1-32.
Fahad Ullah, M. Breast Cancer: Current Perspectives on the Disease Status. In: Ahmad, A. (eds) Breast Cancer Metastasis and Drug Resistance. Advances in Experimental Medicine and Biology, 2019, vol 1152. Springer, Cham.
Jassem J, Krzakowski M, Bobek-Billewicz B, et al., Breast cancer. Oncol Clin Pract 2020; 16(5):207-260.
Trayes, K. P., & Cokenakes, S. Breast Cancer Treatment. American family physician, 2021, 104(2), 171–178.
Harbeck, N., Gnant, M. Breast cancer. Lancet (London, England), 2017, 389(10074), 1134–1150.
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., Pusztai, L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. The Lancet. Oncology, 2019, 20(3), e175–e186.
Yin, L., Duan, J. J., Bian, X. W.,Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast cancer research : BCR, 2020, 22(1), 61.
Lebert, J. M., Lester, R., Powell, E., Seal, M., McCarthy, J. Advances in the systemic treatment of triple-negative breast cancer. Current oncology (Toronto, Ont.), 2018, 25(Suppl 1), S142–S150.
Won, K. A., Spruck, C. Triple negative breast cancer therapy: Current and future perspectives (Review). International journal of oncology, 2020, 57(6), 1245–1261.
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nature reviews. Clinical oncology, 2022, 19(2), 91–113.
Marra, A., & Curigliano, G. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer journal (Sudbury, Mass.), 2021, 27(1), 41–49.
Garufi, G., Palazzo, A., Paris, I., Orlandi, A., Cassano, A., Tortora, G., Scambia, G., Bria, E., & Carbognin, L. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert opinion on pharmacotherapy, 2020, 21(6), 687–699.
Leon-Ferre, R.A., Hieken, T.J. & Boughey, J.C. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Ann Surg Oncol, 2021, 28, 2111–2119.
Keenan, T. E., & Tolaney, S. M. Role of Immunotherapy in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2020, 18(4), 479–489.
Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021). Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica et biophysica acta. Reviews on cancer, 2021, 1876(2), 188593.
Emens LA. Immunotherapy in Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass.)., 2021, Jan-Feb 01;27(1):59-66
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., Iwata, H., Masuda, N., Otero, M. T., Gokmen, E., Loi, S., Guo, Z., Zhao, J., Aktan, G., Karantza, V., Schmid, P., … KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet (London, England), 2020, 396(10265), 1817–1828.
Bartsch R. ASCO 2020: highlights in breast cancer. Memo, 2021, 14(1), 58–61.
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. International journal of environmental research and public health, 2020, 17(6), 2078.
Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-cancer agents in medicinal chemistry, 2017, 17(2), 152–163.
Wang, L., Liu, D., Wu, X., Zeng, Y., Li, L., Hou, Y., Li, W., Liu, Z. Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research. Journal of cellular physiology, 2018, 233(10), 6603–6612.
Sabit, H., Cevik, E., Tombuloglu, H., Abdel-Ghany, S., Tombuloglu, G., Esteller, M. Triple negative breast cancer in the era of miRNA. Critical reviews in oncology/hematology, 2021, 157, 103196
Lyons T. G. Targeted Therapies for Triple-Negative Breast Cancer. Current treatment options in oncology, 2019, 20(11), 82.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Karolina Joanna Ziętara, Mateusz Pawlina, Karolina Widłak, Aleksandra Orzechowska, Karolina Raksa, Katarzyna Nowakowska, Martyna Lewkowicz, Karol Chromiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1122
Number of citations: 0
